Changes in protein expression in p53 deleted spontaneous thymic lymphomas

Experimental Cell Research

Volumn 295, Issue 1, 2004, Pages 91-101

  Honoré, Bent ^a   Vorum, Henrik ^a   Pedersen, Anders Elm ^b   Buus, Søren ^b   Claësson, Mogens H ^b  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

2D PAGE; Mass spectrometry; p53; Protein; Thymic lymphomas; Tumor antigens

Indexed keywords

BLEOMYCIN; CELL PROTEIN; COMPLEMENTARY DNA; GLYOXALASE; PHOSPHOPROTEIN; PROTEIN P53; RIBOSOME PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENE DELETION; GENETIC DISORDER; HUMAN; HUMAN CELL; IMAGE ANALYSIS; LYMPHOMA CELL; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN MOTIF; PROTEIN STRUCTURE; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; THYMUS LYMPHOMA; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 1642420368     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2003.11.029     Document Type: Article

References (32)

1. Eliyahu D., Raz A., Gruss P., Givol D., Oren M. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature. 312:1984;646-649.
2. Matlashewski G., Banks L., Pim D., Crawford L. Analysis of human p53 proteins and mRNA levels in normal and transformed cells. Eur. J. Biochem. 154:1986;665-672.
3. Lane D.P., Benchimol S. p53: oncogene or anti-oncogene? Genes Dev. 4:1990;1-8.
4. Caron de Fromentel C., Soussi T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes, Chromosomes Cancer. 4:1992;1-15.
5. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 253:1991;49-53.
6. Jerry D.J., Ozbun M.A. TP53 tumor suppressor gene: structure and function. Bertino J.R. Encyclopedia of Cancer. vol. 4:2002;415-431 Academic Press, Amsterdam.
7. Wang X.W. Role of p53 and apoptosis in carcinogenesis. Anticancer Res. 19:1999;4759-4771.
8. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., Weinberg R.A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4:1994;1-7.
9. Mathiassen S., Lauemoller S.L., Ruhwald M., Claësson M.H., Buus S. Tumor-associated antigens identified by mRNA expression profiling induce protective anti-tumor immunity. Eur. J. Immunol. 31:2001;1239-1246.
10. Andersen M.L., Ruhwald M., Thorn M., Pedersen A.E., Mathiassen S., Buus S., Claësson M.H. Tumor-associated antigens identified by mRNA expression profiling as tumor rejection epitopes. J. Immune Based Ther. Vaccines. 1:2003;1.
11. Honoré B., Østergaard M. Transcriptomics and proteomics: integration? Cooper D.N. Nature. Encyclopedia of the Human Genome. vol. 5:2003;579-584 The Nature Publishing Group, London.
12. Sun K.H., Tang S.J., Lin M.L., Wang Y.S., Sun G.H., Liu W.T. Monoclonal antibodies against human ribosomal P proteins penetrate into living cells and cause apoptosis of Jurkat T cells in culture. Rheumatology. 40:2001;750-756.
13. Nacht M., Jacks T. V(D)J recombination is not required for the development of lymphoma in p53-deficient mice. Cell Growth Differ. 9:1998;131-138.
14. Guidos C.J., Williams C.J., Grandal I., Knowles G., Huang M.T., Danska J.S. V(D)J recombination activates a p53-dependent DNA damage checkpoint in scid lymphocyte precursors. Genes Dev. 10:1996;2038-2054.
15. Jiang D., Lenardo M.J., Zuniga-Pflucker C. p53 prevents maturation to the CD4+ CD8+ stage of thymocyte differentiation in the absence of T cell receptor rearrangement. J. Exp. Med. 183:1996;1923-1928.
16. Haks M.C., Krimpenfort P., van den Brakel J.H., Kruisbeek A.M. Pre-TCR signaling and inactivation of p53 induces crucial cell survival pathways in pre-T cells. Immunity. 11:1999;91-101.
17. Krowczynska A.M., Coutts M., Makrides S., Brawerman G. The mouse homologue of the human acidic ribosomal phosphoprotein PO: a highly conserved polypeptide that is under translational control. Nucleic Acids Res. 17:1989;6408.
18. Barnard G.F., Staniunas R.J., Bao S., Mafune K., Steele G.D. Jr., Gollan J.L., Chen L.B. Increased expression of human ribosomal phosphoprotein P0 messenger RNA in hepatocellular carcinoma and colon carcinoma. Cancer Res. 52:1992;3067-3072.
19. Kondoh N., Wakatsuki T., Ryo A., Hada A., Aihara T., Horiuchi S., Goseki N., Matsubara O., Takenaka K., Shichita M., Tanaka K., Shuda M., Yamamoto M. Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res. 59:1999;4990-4996.
20. Kesmir C., Nussbaum A.K., Schild H., Detours V., Brunak S. Prediction of proteasome cleavage motifs by neural networks. Protein Eng. 15:2002;287-296.
21. Stryhn A., Pedersen L.O., Romme T., Holm C.B., Holm A., Buus S. Peptide binding specificity of major histocompatibility complex class I resolved into an array of apparently independent subspecificities: quantitation by peptide libraries and improved prediction of binding. Eur. J. Immunol. 26:1996;1911-1918.
22. Andersen M.L., Ruhwald M., Nissen M.H., Buus S., Claësson M.H. Self-peptides with intermediate capacity to bind and stabilize MHC Class I molecules may be immunogenic. Scand. J. Immunol. 57:2003;21-27.
23. Grabowski D.T., Pieper R.O., Futscher B.W., Deutsch W.A., Erickson L.C., Kelley M.R. Expression of ribosomal phosphoprotein PO is induced by antitumor agents and increased in Mer-human tumor cell lines. Carcinogenesis. 13:1992;259-263.
24. Bush J.A., Li G. Cancer chemoresistance: the relationship between p53 and multidrug transporters. Int. J. Cancer. 98:2002;323-330.
25. Bush J.A., Li G. Regulation of the Mdr1 isoforms in a p53-deficient mouse model. Carcinogenesis. 23:2002;1603-1607.
26. Vonderheide R.H., Hahn W.C., Schultze J.L., Nadler L.M. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 10:1999;673-679.
27. Theobald M., Biggs J., Dittmer D., Levine A.J., Sherman L.A. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. U. S. A. 92:1995;11993-11997.
28. Vierboom M.P., Zwaveling S., Bos G.M.J., Ooms M., Krietemeijer G.M., Melief C.J., Offringa R. High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. Cancer Res. 60:2000;5508-5513.
29. Anderson L., Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis. 18:1997;533-537.
30. Gygi S.P., Rochon Y., Franza B.R., Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol. Cell. Biol. 19:1999;1720-1730.
31. Nawrocki A., Fey S.J., Goffeau A., Roepstorff P., Larsen P.M. The effects of transcription regulating genes PDR1, pdr1-3 and PDR3 in pleiotropic drug resistance. Proteomics. 1:2001;1022-1032.
32. He C., Merrick B.A., Patterson R.M., Selkirk J.K. Altered protein synthesis in p53 null and hemizygous transgenic mouse embryonic fibroblasts. Appl. Theor. Electrophor. 5:1995;15-24.